⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NSRX News
Nasus Pharma Ltd.
Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder
globenewswire.com
NSRX
Nasus Pharma CEO Issues 2025 Letter to Shareholders
globenewswire.com
NSRX
Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer
globenewswire.com
NSRX
PRO
BCLI
TEVA
Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed
globenewswire.com
NSRX
Nasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder
globenewswire.com
NSRX
Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program
globenewswire.com
NSRX